Drug Lowered Mortality Rates for PAH
(Ivanhoe Newswire) – The drug macitentan lowered mortality and morbidity rates in patients with pulmonary arterial hypertension (PAH), according to recent research.
The research team randomly assigned the drug or a placebo to 792 patients in a blind study. Researchers found nearly 35 percent of patients who received the drug reached the end point of death or the worsening of symptoms, compared to 46 percent who received the placebo. This trial was different from previous trials with the drug, which had an end-point of exercise capacity.
For more information, go to: http://www.nejm.org/
SOURCE: New England Journal of Medicine, August 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.